Real-world multicenter experience with four-week pegunigalsidase-alfa dosing in Fabry disease (SSIEM 2026) - Aug 17, 2026 - Abstract #P-351; Pres time: Aug 26, 2026; 05:30 PM - 06:30 PM; Location: Hall 4&5; "Clinical stability and good tolerability were observed, suggesting a potential reduction in treatment burden and improved adherence. Further studies with larger cohorts and longer follow-up are required to confirm long-term outcomes."
Clinical • Real-world • Real-world evidence • Atrial Fibrillation • Cardiovascular • Fabry Disease • Genetic Disorders • Otorhinolaryngology • Renal Disease
|
|
Alicia Ugena Garcia 2; Montserrat Morales Conejo 1,5; Ismael Calero Paniagüa 2; Adrián Gómez García-Consuegra 2; Irene Zamora Alarcón 2; Cristina Gonzalez Cegarra 2; Sergio Portilla Prios 2; Pilar Berruga Perez 2; Ana Belén Mañogil Sánchez 2; Lorena Hernandez Martinez 2; Lucia Rojas Cabellos 2; Harol García Arévalo 2
|